Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:delta-9-tetrahydrocannabinol
cannabidiol |
| gptkbp:administeredBy |
oral mucosal spray
|
| gptkbp:alsoKnownAs |
nabiximols
|
| gptkbp:approvedBy |
gptkb:Canada
gptkb:United_Kingdom several European countries |
| gptkbp:ATCCode |
gptkb:N02BG10
|
| gptkbp:availableOn |
oromucosal spray
|
| gptkbp:contains |
1:1 ratio of THC and CBD
|
| gptkbp:controlledSubstanceSchedule |
true
|
| gptkbp:derivedFrom |
Cannabis
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sativex
|
| gptkbp:isApprovedDrug |
true
|
| gptkbp:isNotApprovedIn |
gptkb:United_States
|
| gptkbp:manufacturer |
gptkb:GW_Pharmaceuticals
|
| gptkbp:sideEffect |
nausea
dizziness fatigue somnolence |
| gptkbp:usedFor |
peripheral neuropathy
cancer pain multiple sclerosis spasticity |
| gptkbp:wasFirstApprovedIn |
2005
|
| gptkbp:bfsParent |
gptkb:GW_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|